Year None20242023202220212020201920182017 Jan 05, 2024 Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jan 03, 2024 Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ Cancers Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Displaying 11 - 12 of 12
Jan 03, 2024 Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ Cancers